No headlines found.
Globe Newswire (Wed, 19-Nov 8:00 AM ET)
Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering
Globe Newswire (Fri, 10-Oct 9:54 AM ET)
Globe Newswire (Thu, 9-Oct 8:55 AM ET)
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Aptorum Group Limited - Class A trades on the NASDAQ stock market under the symbol APM.
As of December 19, 2025, APM stock price declined to $1.13 with 34,393 million shares trading.
APM has a beta of 2.13, meaning it tends to be more sensitive to market movements. APM has a correlation of 0.07 to the broad based SPY ETF.
APM has a market cap of $9.20 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, APM traded as high as $17.49 and as low as $.46.
APM has outperformed the market in the last year with a return of +49.5%, while the SPY ETF gained +17.3%. However, in the most recent history, APM shares have underperformed the stock market with its stock returning -41.1% in the last 3 month period and -19.3% for the last 2 week period, while SPY has returned +3.3% and -0.6%, respectively.
APM support price is $1.06 and resistance is $1.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APM shares will trade within this expected range on the day.
